Pliant Therapeutics reports Q2 EPS (71c), consensus (68c)

Reports Q2 cash, cash equivalents and short-term investments of $264.4M. The company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis. “While our activities in the quarter focused on the closure of BEACON-IPF and workforce realignment, we also took actions to ensure that we maintain core capabilities in support of Pliant’s next steps,” said Bernard Coulie, M.D., Ph.D., president and CEO of Pliant. “At the center is a deeply experienced late-stage clinical and regulatory development organization positioned to execute advanced trials. We remain committed to delivering shareholder value and look forward to providing updates in the future.”